TrialBreast cancer research and treatment2024

Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).

Toshimi Takano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.